CMS New Tech Add-On Interpretation Contested By Industry Reps

Medtronic will attempt to persuade CMS that the firm's Kinetra deep-brain stimulation device marks a substantial clinical improvement over its predecessor - the dual-implant Soletra - and therefore qualifies for a new technology "add-on" payment